Drugs / Macitentan 10 mg/Tadalafil 20mg FDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05236231 | Feb → May 2022 | — | Actelion | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Macitentan 10 mg/Tadalafil 20mg FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05236231 ↗ |
| Route | Oral | “will be administered orally as single dose tablets.” NCT05236231 ↗ |